SCHEMBL6985555

SCHEMBL6985555

CCOC(=O)c1ccc(C#N)c(-c2c3ccccc3cc3ccccc23)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.49
ALDH1A1 P00352 4/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
MAPT P10636 3/20 0.49
MEN1 O00255 2/20 0.49
HCRTR1 O43613 2/20 0.49
RAB9A P51151 2/20 0.49
KMT2A Q03164 2/20 0.49
CDC25B P30305 3/20 0.47
APAF1 O14727 1/20 0.47
CASP3 P42574 1/20 0.47
CASP6 P55212 1/20 0.47
SENP8 Q96LD8 1/20 0.47
SENP7 Q9BQF6 1/20 0.47
SENP6 Q9GZR1 1/20 0.47
HSD17B10 Q99714 2/20 0.44
HTT P42858 1/20 0.44
TDP1 Q9NUW8 2/20 0.44
CDC25A P30304 1/20 0.43
CDC25C P30307 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7571390 0.90 KDM4E (0.46) KDM4EALDH1A1SMN1; SMN2MAPTMEN1
SCHEMBL7569863 0.86 MAPT (0.46) KDM4EALDH1A1SMN1; SMN2MAPTMEN1
SCHEMBL7571218 0.86 CDC25B (0.50) KDM4EALDH1A1SMN1; SMN2MAPTMEN1
SCHEMBL7571121 0.81 KDM4E (0.50) KDM4EALDH1A1SMN1; SMN2MAPTMEN1
SCHEMBL6984663 0.81 CACNA1C (0.48) KDM4EALDH1A1SMN1; SMN2MAPTMEN1
SCHEMBL2184105 0.80 SMN1; SMN2 (0.50) KDM4EALDH1A1SMN1; SMN2MAPTMEN1
SCHEMBL7571144 0.79 MAPT (0.47) KDM4EALDH1A1SMN1; SMN2MAPTMEN1
SCHEMBL7571031 0.78 MAPT (0.49) KDM4EALDH1A1SMN1; SMN2MAPTMEN1
SCHEMBL7575014 0.77 KDM4E (0.47) KDM4EALDH1A1SMN1; SMN2MAPTMEN1
SCHEMBL7575780 0.77 HSD17B2 (0.51) KDM4EALDH1A1SMN1; SMN2MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1276726-A2 SUBSTITUTED PHENYL FARNESYLTRANSFERASE INHIBITORS Abbott Laboratories (US) 2003-01-22 EP disclosed
US-20020019527-A1 Substituted phenyl farnesyltransferase inhibitors ABBOTT LABORATORIES 2002-02-14 US disclosed
WO-2001081316-A2 SUBSTITUTED PHENYL FARNESYLTRANSFERASE INHIBITORS ABBOTT LABORATORIES (US) 2001-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019527-A1 Substituted phenyl farnesyltransferase inhibitors FNTA, FNTB, SLC10A1 KDM4E 3715/4885ALDH1A1 385/4885SMN1; SMN2 4187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.